RepliCel Announces Stock Option Grant

Marketwired

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sep 6, 2013) - RepliCel Life Sciences Inc. (REPCF)(CNSX:RP), a clinical stage biopharmaceutical company focused on the development of autologous cell therapies, announces that pursuant to its Stock Option Plan, the Company granted 1,310,000 options to various employees and consultants of the Company. The options vest over a three year period and are exercisable at $0.55 per share until September 5, 2020.

About RepliCel Life Sciences

RepliCel is a clinical stage biopharmaceutical company focused on developing autologous cell therapies. RepliCel Hair-01 (RCH-01) is a cellular treatment for androgenetic alopecia (pattern baldness). Shiseido Company, Limited has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China and South Korea. RepliCel Tendon-01 (RCT-01) is a cell therapy for the treatment of chronic tendon injuries. Both product candidates are based on RepliCel's innovative technology which utilizes cells isolated from a patient's own healthy hair follicles to address specific cellular deficits. Phase II clinical trials, for both programs, are planned for the later part of 2013. For additional information please visit www.replicel.com.

Notice Regarding Forward Looking Statements

This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements that relate to the approval and commercialization of the Company's hair restoration process, the Company's development of its Achilles tendon technology and the expected commencement of the Company's Phase II clinical trial for its tendon technology. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company's clinical trials; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2012 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on Sedar at www.sedar.com.

Contact:
Tammey George
Director of Communications
RepliCel Life Sciences
604-248-8696
tg@replicel.com
INVESTOR CONTACTS:
Westwicke Partners, LLC
Stefan Loren, Ph.D.
Managing Director
(443) 213-0507
sloren@westwicke.com
Robert H. Uhl
Managing Director
(858) 356-5932
robert.uhl@westwicke.com

Rates

View Comments (0)